virus
exist
wherev
life
common
pathogen
lead
infecti
fatal
human
diseas
accord
world
health
organ
report
million
peopl
live
human
immunodefici
viru
hiv
recent
estim
indic
hepat
c
viru
hcv
caus
chronic
infect
approxim
world
addit
two
viral
pathogen
human
also
constantli
encount
threat
mani
emerg
reemerg
infecti
zoonot
devast
virus
highli
pathogen
avian
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
middl
east
respiratori
syndrom
coronaviru
ebola
viru
ebov
given
high
mutat
rate
virus
seriou
threat
public
health
high
urgenc
develop
new
antivir
drug
combat
pathogen
natur
product
root
stem
bark
leav
fruit
seed
plant
use
herbal
medicin
treat
diseas
year
china
also
play
signific
role
modern
drug
discoveri
serv
prototyp
novel
drug
mention
newman
et
estim
clinic
use
antitumor
drug
around
end
natur
product
deriv
natur
drug
also
crucial
antivir
drug
discoveri
antivir
drug
clinic
use
natur
product
design
use
natur
product
prototyp
among
natur
product
triterpenoid
rel
also
call
steroid
constitut
larg
famili
compound
identifi
molecul
mani
new
compound
discov
plant
anim
fungi
everi
exist
natur
free
acid
ester
fatti
acid
ferul
acid
etc
triterpenoid
saponin
link
one
sugar
chain
often
main
activ
constitu
mani
import
medicin
plant
ginsenosid
panax
ginseng
glycyrrhizin
glycyrrhiza
uralensi
saikosaponin
radix
triterpenoid
display
varieti
structur
nearli
differ
skeleton
known
natur
sourc
enzymat
reaction
although
mani
variant
smaller
number
common
structur
mani
pentacycl
triterpenoid
pt
show
wide
rang
pharmacolog
activ
market
therapeut
agent
dietari
structur
pt
four
ring
call
b
c
ring
e
base
carbon
skeleton
divid
six
common
subgroup
oleanan
lupan
ursan
friedelan
hopan
gammaceran
fig
pt
larg
class
secondari
plant
metabolit
construct
isopren
unit
abund
natur
product
linear
triterpen
squalen
major
constitu
shark
liver
oil
deriv
two
farnesyl
pyrophosph
unit
catalysi
squalen
epoxidas
squalen
biosynthet
oxid
variou
cyclic
product
yield
dammarenyl
lupenyl
baccharenyl
cation
intermedi
eventu
give
rise
three
major
product
name
lupeol
respect
fig
mani
pt
hydroxyl
group
carboxyl
acid
structur
divers
pt
provid
uniqu
group
agent
varieti
pharmacolog
includ
antivir
antitumor
immunomodulatori
hepatoprotect
activ
present
newli
discov
pt
subject
annual
review
reflect
increas
import
class
avail
review
cover
antitumor
pharmacolog
recent
antivir
activ
pt
attract
increas
attent
japan
stronger
snmc
prepar
contain
glycyrrhizin
glycyrrhiz
acid
use
treatment
chronic
hepat
diseas
year
glycyrrhetin
acid
ga
fig
pt
deriv
type
obtain
hydrolysi
glycyrrhizin
isol
herb
liquoric
show
inhibit
varieti
virus
includ
hepat
b
viru
hbv
saponin
two
triterpenoid
isol
soybean
seed
report
activ
hiv
concentr
greater
mgml
three
year
later
chen
et
al
report
salasperm
acid
anoth
triterpen
deriv
isol
tripterygium
wilfordii
block
replic
hiv
lymphocyt
afterward
fujioka
et
al
found
betulin
acid
ba
isol
leav
bark
syzigium
claviflorum
also
show
signific
activ
hiv
sinc
natur
pt
report
antivir
activ
well
known
lipid
class
hydrophob
biomolecul
import
cellular
life
especi
viru
entri
host
cell
report
promiscu
antivir
activ
natur
pt
might
relat
effect
lipid
synthet
chemist
becom
interest
scaffold
due
potenti
antivir
properti
lead
product
varieti
pt
deriv
modif
function
group
deriv
use
clinic
drug
treatment
diseas
other
variou
phase
clinic
exampl
ba
deriv
bevirimat
bvm
also
known
ba
dsb
found
exhibit
remark
activ
primari
hiv
repres
uniqu
first
class
compound
term
matur
inhibitor
mi
due
baselin
gag
polymorph
posit
reduc
sensit
bevirimat
halt
develop
recent
second
class
potent
pt
develop
oral
treatment
hiv
howev
review
focus
activ
pt
viral
focu
present
review
summar
recent
advanc
antivir
activ
action
model
pt
aid
antivir
drug
develop
pt
entri
host
cell
first
phase
viral
replic
cycl
order
multistep
process
involv
attach
viru
host
cell
bind
viru
fusion
cell
viral
membran
use
multipl
pathway
usurp
cellular
transport
surf
along
cell
process
provid
target
develop
novel
entri
inhibitor
prevent
hiv
infect
first
step
glycyrrhizin
triterpenoid
saponin
isol
licoric
root
report
possess
infect
activ
block
adsorpt
particl
onto
compound
fig
analogu
glycyrrhizin
heteroannular
dien
structur
c
ring
demonstr
activ
glycyrrhizin
infect
cytopathogen
complet
inhibit
compound
concentr
mm
howev
underli
mechan
kind
compound
remain
unclear
ba
deriv
aminooctanoyl
acid
side
chain
shown
potent
inhibitor
membran
fusion
valu
compound
vari
rang
nm
cell
system
select
index
excess
transmembran
glycoprotein
initi
report
target
mutat
lai
suffici
drug
resist
studi
illustr
sequenc
loop
stabil
complex
affect
antivir
efficaci
stereoisom
found
equal
activ
valu
interact
chang
structur
acceptor
two
ba
deriv
block
adsorpt
hiv
host
cell
addit
compound
isom
show
highest
activ
magi
fusion
assay
lymphocyt
hiv
rtase
catalyz
replic
viru
rna
dna
inhibit
rtase
enzym
disrupt
essenti
process
viru
replic
infect
therefor
rtase
long
obviou
target
battl
hiv
mimusop
acid
triterpen
analogu
isol
seed
mimusop
elengi
report
possess
weak
inhibitori
activ
micromolar
pengsuparp
et
al
report
acid
isol
root
maprounea
africana
also
rtase
activ
valu
hiv
polyprotein
contain
sever
viral
protein
join
togeth
must
cleav
individu
function
protein
cleavag
catalyz
hiv
proteas
symmetr
homodim
inhibit
hiv
proteas
prevent
enzym
cut
viral
protein
molecul
proper
size
make
hiv
proteas
promis
drug
target
ursol
acid
ua
hydrogen
malon
isol
stem
cynomorium
songaricum
activ
inhibit
proteas
valu
micromolar
level
glutaryl
hemiest
ba
ua
shown
proteas
activ
concentr
oleanol
acid
oa
xanthocera
sorbifolia
found
complet
inhibit
proteas
activ
concentr
chemic
modif
triterpen
andor
increas
proteas
activ
potent
compound
show
proteas
activ
rang
addit
escin
ia
ib
two
triterpen
saponin
isol
aesculu
chinensi
also
exhibit
proteas
inhibitori
mi
emerg
class
compound
block
matur
specif
interf
gag
process
cascad
final
step
viral
replic
cycl
matrix
protein
capsid
protein
ca
nucleocapsid
protein
nc
protein
releas
gag
polyprotein
precursor
repres
novel
target
potenti
intervent
inhibit
gag
lead
defect
core
condens
releas
noninfecti
viru
particl
host
cell
thu
lead
releas
noninfect
particl
bevirimat
mi
studi
human
recent
sever
mi
show
improv
potenc
virus
contain
gag
polymorph
develop
clinic
trial
hiv
patient
introduct
group
hydroxyl
oa
gener
potent
compound
greatli
increas
potenc
without
signific
cytotox
compound
shown
activ
subnanomolar
concentr
therapeut
index
similarli
introduct
group
posit
ba
lead
discoveri
bevirimat
compound
greatli
increas
activ
ba
valu
less
nm
select
index
structur
report
literatur
oral
bioavail
small
molecul
hiv
therapi
develop
myrexi
block
replic
interrupt
process
viral
capsid
protein
condens
form
conic
core
structur
surround
viral
genom
phase
clinic
trial
healthi
volunt
complet
primari
object
studi
evalu
safeti
toler
pharmacodynam
result
show
overal
safeti
profil
favor
observ
pharmacokinet
pk
pharmacodynam
pd
profil
support
continu
research
mi
ineffect
natur
occur
variat
polymorph
gag
proteas
polyprotein
howev
inhibitor
develop
better
toler
gag
oral
activ
hiv
mi
develop
squibb
treatment
hiv
infect
compound
phase
iib
clinic
trial
discontinu
block
matur
viru
prevent
viral
reproduct
host
cell
nm
wt
nm
wt
variant
gag
protein
anoth
inhibitor
also
clinic
investig
ba
deriv
modif
ba
block
viru
fusion
viru
matur
simultan
novel
type
bifunct
inhibitor
combin
entri
pharmacophor
matur
pharmacophor
bevirimat
bifunct
compound
acid
obtain
doubl
strike
life
cycl
hiv
present
best
activ
valu
propos
hcv
glycoprotein
could
essenti
drug
target
develop
hcv
entri
core
structur
protein
solv
result
mani
agent
investig
inhibitor
interrupt
interact
thu
inhibit
hcv
small
molecul
design
synthes
mimic
interact
space
hydrophob
featur
helix
region
show
promis
activ
inhibitori
compound
effect
express
disrupt
associ
cell
surfac
protein
bind
pt
show
fair
activ
entri
oa
echinocyst
acid
ea
fig
two
natur
occur
triterpen
deriv
display
potent
activ
hcv
entri
yu
et
al
report
oa
show
weak
entri
activ
howev
small
modif
structur
introduct
hydroxyl
group
provid
analogu
lead
significantli
enhanc
activ
valu
hcvpp
lead
compound
comprehens
relationship
sar
studi
conduct
introduc
disaccharid
lead
compound
lead
discoveri
compound
show
stronger
entri
activ
without
undesir
hemolyt
effect
format
triterpen
dimer
via
linker
result
discoveri
compound
valu
seri
bival
triterpen
design
synthes
optim
hydrophob
rigid
length
linker
found
compound
exhibit
dramat
enhanc
activ
valu
subnanomolar
well
known
low
solubl
biolog
matrix
high
hydrophob
pt
hinder
applic
particularli
develop
therapeut
agent
given
limit
solubl
pt
seri
cd
conjug
synthes
improv
solubl
maintain
activ
base
hcvppvsvgpp
entri
assay
valu
compound
show
elev
water
solubl
maintain
activ
entri
elucid
pharmacophor
ea
microbi
transform
strategi
ring
expansionopen
strategi
use
explor
result
show
metabolit
gener
microbi
transform
exhibit
improv
activ
except
compound
display
similar
even
littl
higher
potenc
hcv
entri
assay
meanwhil
ring
expans
ring
open
deriv
ea
lacton
acid
pentol
show
improv
activ
studi
show
ring
c
ea
highli
conserv
chemic
modif
two
ring
abolish
potenc
suggest
steric
hinder
effect
rigid
skeleton
play
import
role
determin
entri
activ
summari
chemic
explor
triterpen
compound
reveal
ring
right
side
ring
e
toler
modif
ring
b
c
left
side
ring
e
highli
conserv
entri
activ
introduc
hydroxyl
group
ring
enhanc
potenc
triterpen
remov
hemolyt
effect
ea
fig
oa
also
found
hcv
proteas
base
lead
compound
oa
deriv
synthes
test
inhibitori
activ
hepat
c
viral
proteas
deriv
dicarboxyl
acid
hemiest
show
potent
activ
hcv
proteas
dicarboxyl
acid
hemiest
two
compound
rel
short
carbon
chain
show
much
lower
cytotox
oa
maintain
inhibitori
activ
hcv
proteas
deriv
soyasapogenol
b
inhibit
hcv
replic
induc
oligoadenyl
synthetas
gene
express
enhanc
effect
interferon
ifn
increas
gene
express
vitro
assay
reduc
hcv
core
antigen
hcvcag
level
mous
moreov
also
found
induc
interleukin
stimul
product
protect
mous
acut
liver
injuryfailur
induc
concanavalin
con
prevent
develop
alcohol
fatti
phase
trial
carri
show
strongli
reduc
posit
neg
rna
strand
level
measur
polymeras
chain
reaction
pcr
glycyrrhizin
shown
inhibitori
activ
variou
virus
includ
hiv
herp
simplex
viru
hsv
vesicular
stomat
viru
vsv
hbv
compound
also
show
proteas
activ
valu
synergist
effect
compound
ifn
hcv
observ
provid
new
treatment
along
ifn
hcv
infect
suggest
activ
constitu
trigger
pathway
led
induct
secret
antivir
activ
seri
dna
rna
glycyrrhizin
isol
root
licoric
show
broad
antivir
wolkerstorf
et
al
investig
mechan
inhibit
influenza
viru
infect
found
compound
interact
membran
cell
lead
decreas
cell
endocytot
activ
viru
lead
compound
deriv
develop
among
compound
exhibit
effici
activ
fig
recent
uralsaponin
novel
triterpenoid
saponin
isol
root
g
uralensi
shown
exhibit
inhibitori
activ
influenza
viru
canin
kidney
mdck
cell
valu
song
et
al
report
conjug
pt
chacotrios
could
inhibit
entri
highli
pathogen
influenza
viru
mdck
cell
vari
compound
substitut
methyl
ursol
deriv
show
potent
viru
entri
activ
anoth
work
chacotriosyl
aglycon
moieti
report
import
effect
activ
influenza
viru
activ
could
improv
disubstitut
amid
introduc
introduct
dimethylamin
provid
compound
show
potent
activ
view
broad
antivir
spectrum
group
establish
viru
drug
screen
model
screen
base
plaqu
format
inhibit
assay
acetyl
conjug
acetyl
conjug
found
best
activ
addit
exhibit
broad
spectrum
rang
tabl
importantli
lead
compound
show
tendenc
induc
resist
influenza
virus
suggest
may
potenti
overcom
antivir
drug
resist
explor
mechan
action
indic
could
block
attach
influenza
viru
particl
membran
host
cell
bind
sialic
acid
pocket
influenza
viral
ha
protein
fig
multival
ligand
show
much
higher
bind
affin
homotrimer
influenza
ha
receptor
recent
group
design
synthes
seri
multival
cd
conjug
enhanc
affin
pt
ha
thu
improv
potenc
influenza
multival
conjug
found
show
potent
antivir
activ
influenza
viru
potent
monoval
conjug
studi
action
mechan
show
multival
conjug
could
also
bind
influenza
viral
ha
protein
thu
inhibit
attach
influenza
viru
particl
host
cell
fig
recent
cd
deriv
found
improv
solubl
organ
water
basi
previou
group
prepar
multival
conjug
evalu
vitro
activ
two
conjug
identifi
exhibit
highest
viru
activ
micromolar
level
respect
si
conjug
pt
bioactiv
compound
acid
sialic
acid
also
use
strategi
prepar
new
biolog
pt
conjug
found
potent
antivir
activ
influenza
viru
valu
hong
et
al
report
ba
isol
jujub
tree
zizyphu
jujub
mill
exhibit
antivir
activ
influenza
viru
vitro
two
ba
deriv
isol
chines
herbal
medicin
schefflera
heptaphylla
found
inhibitori
activ
influenza
viru
valu
respect
tung
et
al
report
betulin
aldehyd
isol
alnu
japonica
exhibit
effect
influenza
viru
furthermor
report
betulin
show
high
activ
influenza
viru
low
cytotox
select
index
si
among
pt
glycyrrhizin
deriv
first
report
activ
cinatl
et
inhibitor
present
mm
replic
si
cell
addit
inhibit
viral
replic
also
abl
inhibit
adsorpt
well
penetr
viru
begin
stage
life
cycl
compound
effect
treat
adsorpt
process
adsorpt
process
mm
vs
mm
respect
moreov
given
adsorpt
period
show
potent
activ
shown
chang
glycosid
chain
introduct
heterocycl
fragment
amino
acid
obvious
affect
antivir
activ
deriv
case
hoever
et
al
evalu
activ
pt
compound
potent
deriv
show
tenfold
increas
bioactiv
produc
introduct
carbohydr
chain
fig
inhibit
replic
respect
compound
show
similar
effect
compound
effect
micromolar
level
deriv
also
demonstr
sever
cytotox
result
decreas
select
index
rang
result
show
chemic
embellish
introduct
conh
bond
abl
enhanc
antiviru
effect
hover
also
found
ga
partial
hydrolyz
exhibit
high
activ
well
toxic
consid
mechan
activ
hover
specul
entri
process
cell
block
attach
carbohydr
demonstr
necessari
viral
entri
host
cell
wu
et
al
found
deriv
show
activ
concentr
minim
concentr
inhibit
toward
wen
et
al
evalu
compound
includ
two
pt
betulon
acid
activ
cell
base
cytopath
effect
cpe
assay
tabl
compar
whose
valu
valu
lower
posit
control
valinomycin
valu
compound
si
compound
indic
effect
inhibit
viral
replic
without
obviou
cytotox
two
compound
test
inhibit
assay
toward
proteas
compound
demonstr
valid
inhibitori
effect
proteas
function
valu
k
valu
indic
competit
inhibit
mode
action
howev
comput
dock
analysi
reveal
abl
occupi
bind
pocket
proteas
moreov
bind
enhanc
format
hydrogen
bond
c
proteas
contrari
form
intermolecular
bond
pocket
besid
hydrophob
interact
activ
could
result
combin
two
differ
antivir
mechan
one
via
proteas
inhibit
via
block
entri
post
bind
step
fusion
viru
particl
host
cell
membran
also
import
gener
antivir
mechan
pt
ryu
isol
four
triterpen
triterygium
regelii
compound
smoothli
convert
deriv
hydrogen
five
compound
test
proteas
inhibitori
activ
tabl
valu
four
separ
triterpen
around
synthes
phenol
moieti
show
lower
activ
result
demonstr
presenc
moieti
exert
rel
signific
effect
inhibit
moreov
isol
inhibitor
mode
competit
inhibit
k
valu
potent
compound
determin
hydroxyl
group
form
firm
hydrogen
bond
oxygen
atom
carbonyl
group
oh
pocket
wherea
form
hydrophob
interact
pt
deriv
show
activ
differ
step
life
cycl
suggest
pt
block
replic
complex
mechan
though
unclear
proteas
attract
target
develop
drug
hbv
belong
hepadnavirida
famili
character
high
hbv
infect
global
health
threat
million
hbv
carrier
worldwid
risk
develop
liver
sever
agent
undergon
clinic
trial
treat
hbv
infect
howev
problem
aros
clinic
trial
challeng
use
exampl
nucleotid
analog
lamivudin
adefovir
ifn
current
use
treat
chronic
hbv
patient
frequent
relaps
recoveri
limit
therefor
novel
hbv
inhibitor
urgent
need
glycyrrhizin
use
treat
hbv
mani
year
vitro
vivo
experi
conduct
test
mechan
studi
show
treatment
inhibit
secret
hepat
b
surfac
antigen
hbsag
vitro
addit
romero
et
al
report
moder
abil
inhibit
hbv
dna
releas
cell
sato
et
al
determin
sar
glycyrrhizin
ga
ga
hbv
three
compound
compound
show
potent
inhibit
activ
hbsag
secret
howev
guinea
pig
studi
ga
detect
liver
fraction
even
administr
excess
dose
glycyrrhizin
glycyrrhizin
main
compound
liver
fraction
intraven
administr
suggest
glycyrrhizin
would
play
import
role
treatment
patient
chronic
hepat
tibetan
herb
potentilla
anserin
l
wide
use
china
treat
hepat
b
compound
fig
isol
rhizom
p
anserin
l
found
inhibitori
activ
hbsag
hbeag
secret
hbv
dna
releas
vitro
respect
vivo
studi
indic
compound
could
inhibit
hbv
dna
pulsatilla
chinensi
anoth
tradit
chines
herb
show
efficaci
hbv
clearanc
hbv
patient
far
compon
isol
p
chinensi
test
hbv
clearanc
activ
among
ba
deriv
identifi
activ
yao
et
al
found
ba
could
inhibit
express
manganes
superoxid
dismutas
subsequ
gener
reactiv
oxygen
speci
ro
compound
could
inhibit
hbv
replic
vitro
hsv
belong
herpesvirida
famili
caus
seriou
public
health
world
health
organ
report
world
popul
age
current
acyclovir
deriv
approv
fda
treat
hsv
howev
toxic
side
effect
emerg
hsv
viru
strain
limit
therefor
novel
hsv
inhibitor
need
medicin
herb
rhu
javanica
report
kurokawa
et
al
isol
two
major
compound
moron
acid
fig
herb
evalu
activ
vitro
effect
concentr
plaqu
reduct
hsv
type
respect
therapeut
index
larger
suscept
acyclovir
phosphonoacet
thymidin
hsv
type
similar
indic
broad
antivir
spectrum
hsv
ikeda
et
al
studi
sar
triterpenoid
includ
glycyrrhizin
sapogenol
result
show
glycyrrhet
acid
sapogenol
glycyrrhizin
much
potent
activ
glycyrrhizin
addit
found
soyasapogenol
show
less
activ
soyasapogenol
b
suggest
hydroxyl
might
weaken
antivir
activ
also
found
kudzusapogenol
abrisapogenol
b
abrisapogenol
c
activ
suggest
hydroxyl
group
could
abolish
activ
howev
kudzusapogenol
b
methyl
ester
exhibit
stronger
activ
suggest
methyl
ester
group
could
improv
activ
furthermor
gong
et
al
determin
synergist
effect
betulin
acyclovir
drug
combin
potent
moder
synergist
effect
found
acyclovir
betulin
concentr
higher
respect
synergist
effect
also
found
concentr
acyclovir
betulin
respect
synergist
antivir
effect
suggest
action
mechan
betulin
differ
acyclovir
navid
et
al
explor
action
mechan
found
pt
could
inhibit
earli
stage
hsv
life
human
enteroviru
singl
strand
rna
viru
belong
picornavirida
famili
possess
nonenvelop
ssrna
genom
major
pathogen
hand
foot
mouth
diseas
hfmd
caus
epidem
enceph
acut
flaccid
paralysi
afp
result
cardiopulmonari
failur
death
babi
year
old
still
effect
drug
treat
infect
glycyrrhizin
one
main
compon
isol
glycyrrhiza
spp
mani
kind
antivir
activ
wang
studi
first
recogn
medicin
effect
compound
inhibit
replic
manner
concentr
requir
inhibit
infect
millimolar
rang
reduc
infecti
product
mm
mm
respect
addit
identif
antivir
compon
g
uralensi
wang
et
al
also
reveal
distinct
mechan
block
infect
target
event
cell
entri
ua
pt
isol
aqueou
extract
ocimum
basilicum
also
known
sweet
basil
herb
commonli
use
tradit
chines
medicin
chiang
report
demonstr
strongest
activ
si
si
valu
greater
strong
activ
low
cytotox
indic
potenti
use
treat
infect
tabl
furthermor
action
hr
indic
inhibitori
effect
occur
infect
replic
process
therefor
may
potenti
prevent
effect
well
treatment
effect
song
et
al
report
hederasaponin
b
fig
hedera
helix
compound
could
significantli
decreas
format
visibl
cpe
vero
cell
demonstr
effect
activ
without
obviou
cytotox
tabl
addit
western
blot
assay
show
abl
reduc
express
viral
protein
thu
demonstr
inhibitori
effect
synthesi
viral
capsid
protein
comparison
ribavirin
show
activ
result
indic
promis
drug
candid
variou
subgenotyp
broad
spectrum
antivir
activ
zhao
et
al
evalu
six
newli
synthes
pt
activ
analyz
inhibitori
effect
express
protein
western
blot
analysi
revers
transcript
rt
compound
demonstr
potent
activ
parent
compound
signific
cytotox
found
viru
ebv
one
major
pathogen
infecti
mononucleosi
human
gener
link
two
malign
endem
burkitt
lymphoma
nasopharyng
carcinoma
npc
number
diseas
increas
requir
develop
effect
vaccin
protect
well
novel
antivir
agent
treatment
lin
et
al
report
glycyrrhizin
exhibit
activ
ebv
replic
superinfect
raji
cell
manner
mm
mm
si
time
addit
studi
show
effect
close
associ
event
post
viru
cell
entri
rather
direct
inactiv
viru
block
viru
adsorpt
antivir
mechan
appear
earli
step
ebv
replic
cycl
differ
mechan
nucleosid
analog
target
viral
dna
polymeras
deriv
repres
new
type
agent
chang
first
report
moron
acid
isol
gall
brazilian
propoli
rhu
chinensi
agent
eb
compar
triterpen
novel
mechan
stage
lytic
cycl
ebv
transcript
viral
lytic
gene
activ
rta
zta
two
transcript
factor
express
eb
viru
found
compound
inhibit
function
rta
activ
promot
contain
element
thu
reduc
express
zta
ebv
earli
protein
si
target
compound
rta
one
import
transcript
factor
ebv
compound
use
new
lead
develop
drug
pt
class
plant
metabolit
high
structur
divers
provid
import
sourc
lead
compound
drug
research
develop
pt
deriv
use
prevent
treat
chronic
hepat
diseas
mani
countri
china
japan
addit
gener
show
weak
toxic
howev
valu
pt
prevent
treat
viral
diseas
partial
exploit
bevirimat
undergon
phase
iib
clinic
trial
hiv
mi
recent
mani
research
group
investig
pt
potenti
therapeut
agent
treatment
viru
infect
mani
natur
pt
semisynthet
deriv
report
activ
hiv
hcv
influenza
virus
investig
molecular
basi
antivir
activ
also
progress
rapidli
howev
precis
target
action
mechan
usual
unclear
limit
develop
addit
poor
aqueou
solubl
anoth
major
drawback
variou
applic
particular
develop
drug
intens
explor
lead
design
new
pt
potent
antivir
inhibitor
better
antivir
activ
profil
lower
valu
